R&D ‘Recoupment’ Data Demands To Inform Medicare Negotiation Are Unworkable, CMS Told
Executive Summary
In comments to regulators, manufacturers express concerns about the extensive R&D information being sought as part of the negotiation process. Pharmacy benefit managers also caution against reliance on R&D spending data for pricing decisions, but for a different reason.